Gray platelet syndrome: Difference between revisions
From WikiMD's Wellness Encyclopedia
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
[[File:Autosomal_recessive_-_en.svg| | {{SI}} | ||
{{Infobox medical condition | |||
| name = Gray platelet syndrome | |||
| image = [[File:Autosomal_recessive_-_en.svg|200px]] | |||
| caption = Gray platelet syndrome is inherited in an [[autosomal recessive]] pattern. | |||
| synonyms = GPS | |||
| field = [[Hematology]] | |||
| symptoms = [[Thrombocytopenia]], large platelets, [[myelofibrosis]], bleeding tendency | |||
| complications = [[Bleeding]], [[anemia]] | |||
| onset = [[Congenital]] | |||
| duration = Lifelong | |||
| causes = Mutations in the [[NBEAL2]] gene | |||
| risks = Family history of the condition | |||
| diagnosis = [[Blood smear]], [[bone marrow biopsy]], genetic testing | |||
| differential = Other platelet function disorders | |||
| treatment = [[Platelet transfusion]], [[antifibrinolytic]] agents | |||
| medication = [[Desmopressin]], [[tranexamic acid]] | |||
| prognosis = Variable, depends on severity | |||
| frequency = Rare | |||
}} | |||
'''Gray platelet syndrome''' ('''GPS''') is a rare congenital bleeding disorder characterized by the deficiency or absence of alpha granules in platelets. This condition leads to a variety of clinical manifestations, including mild to moderate bleeding tendencies, myelofibrosis, and splenomegaly. | |||
== Pathophysiology == | == Pathophysiology == | ||
Gray platelet syndrome is caused by mutations in the [[NBEAL2]] gene, which is essential for the development and function of alpha granules in platelets. Alpha granules are storage organelles within platelets that contain proteins crucial for [[blood clotting]] and wound healing. The absence of these granules results in platelets that appear gray under a microscope, hence the name of the syndrome. | Gray platelet syndrome is caused by mutations in the [[NBEAL2]] gene, which is essential for the development and function of alpha granules in platelets. Alpha granules are storage organelles within platelets that contain proteins crucial for [[blood clotting]] and wound healing. The absence of these granules results in platelets that appear gray under a microscope, hence the name of the syndrome. | ||
== Clinical Features == | == Clinical Features == | ||
Patients with Gray platelet syndrome typically present with: | Patients with Gray platelet syndrome typically present with: | ||
| Line 11: | Line 29: | ||
* Menorrhagia (heavy menstrual bleeding) | * Menorrhagia (heavy menstrual bleeding) | ||
* Prolonged bleeding after surgery or dental procedures | * Prolonged bleeding after surgery or dental procedures | ||
In addition to bleeding symptoms, individuals with GPS may develop: | In addition to bleeding symptoms, individuals with GPS may develop: | ||
* [[Myelofibrosis]], a condition characterized by the replacement of bone marrow with fibrous tissue | * [[Myelofibrosis]], a condition characterized by the replacement of bone marrow with fibrous tissue | ||
* [[Splenomegaly]], an enlargement of the spleen | * [[Splenomegaly]], an enlargement of the spleen | ||
== Diagnosis == | == Diagnosis == | ||
The diagnosis of Gray platelet syndrome is based on: | The diagnosis of Gray platelet syndrome is based on: | ||
| Line 23: | Line 39: | ||
* Bone marrow biopsy indicating myelofibrosis | * Bone marrow biopsy indicating myelofibrosis | ||
* Genetic testing confirming mutations in the [[NBEAL2]] gene | * Genetic testing confirming mutations in the [[NBEAL2]] gene | ||
== Treatment == | == Treatment == | ||
There is no specific cure for Gray platelet syndrome. Management focuses on preventing and treating bleeding episodes. Treatment options include: | There is no specific cure for Gray platelet syndrome. Management focuses on preventing and treating bleeding episodes. Treatment options include: | ||
| Line 29: | Line 44: | ||
* Use of antifibrinolytic agents such as [[tranexamic acid]] to reduce bleeding | * Use of antifibrinolytic agents such as [[tranexamic acid]] to reduce bleeding | ||
* Hormonal therapy to manage menorrhagia in women | * Hormonal therapy to manage menorrhagia in women | ||
== Prognosis == | == Prognosis == | ||
The prognosis for individuals with Gray platelet syndrome varies. While many patients experience mild to moderate bleeding symptoms, the development of myelofibrosis can lead to more serious complications. Regular monitoring and supportive care are essential to manage the condition effectively. | The prognosis for individuals with Gray platelet syndrome varies. While many patients experience mild to moderate bleeding symptoms, the development of myelofibrosis can lead to more serious complications. Regular monitoring and supportive care are essential to manage the condition effectively. | ||
== See also == | |||
== | |||
* [[Platelet]] | * [[Platelet]] | ||
* [[Blood clotting]] | * [[Blood clotting]] | ||
| Line 40: | Line 53: | ||
* [[Epistaxis]] | * [[Epistaxis]] | ||
* [[Menorrhagia]] | * [[Menorrhagia]] | ||
== References == | == References == | ||
{{Reflist}} | {{Reflist}} | ||
== External Links == | == External Links == | ||
{{No external links}} | {{No external links}} | ||
{{Hematology}} | {{Hematology}} | ||
{{medicine-stub}} | {{medicine-stub}} | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Genetic disorders]] | [[Category:Genetic disorders]] | ||
[[Category:Rare diseases]] | [[Category:Rare diseases]] | ||
Latest revision as of 01:57, 7 April 2025
Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's medical weight loss NYC, sleep center NYC
Philadelphia medical weight loss and Philadelphia sleep clinics
| Gray platelet syndrome | |
|---|---|
| File:Autosomal recessive - en.svg | |
| Synonyms | GPS |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Thrombocytopenia, large platelets, myelofibrosis, bleeding tendency |
| Complications | Bleeding, anemia |
| Onset | Congenital |
| Duration | Lifelong |
| Types | N/A |
| Causes | Mutations in the NBEAL2 gene |
| Risks | Family history of the condition |
| Diagnosis | Blood smear, bone marrow biopsy, genetic testing |
| Differential diagnosis | Other platelet function disorders |
| Prevention | N/A |
| Treatment | Platelet transfusion, antifibrinolytic agents |
| Medication | Desmopressin, tranexamic acid |
| Prognosis | Variable, depends on severity |
| Frequency | Rare |
| Deaths | N/A |
Gray platelet syndrome (GPS) is a rare congenital bleeding disorder characterized by the deficiency or absence of alpha granules in platelets. This condition leads to a variety of clinical manifestations, including mild to moderate bleeding tendencies, myelofibrosis, and splenomegaly.
Pathophysiology[edit]
Gray platelet syndrome is caused by mutations in the NBEAL2 gene, which is essential for the development and function of alpha granules in platelets. Alpha granules are storage organelles within platelets that contain proteins crucial for blood clotting and wound healing. The absence of these granules results in platelets that appear gray under a microscope, hence the name of the syndrome.
Clinical Features[edit]
Patients with Gray platelet syndrome typically present with:
- Mild to moderate bleeding diathesis
- Easy bruising
- Epistaxis (nosebleeds)
- Menorrhagia (heavy menstrual bleeding)
- Prolonged bleeding after surgery or dental procedures
In addition to bleeding symptoms, individuals with GPS may develop:
- Myelofibrosis, a condition characterized by the replacement of bone marrow with fibrous tissue
- Splenomegaly, an enlargement of the spleen
Diagnosis[edit]
The diagnosis of Gray platelet syndrome is based on:
- Clinical history and physical examination
- Complete blood count (CBC) showing normal or slightly reduced platelet count
- Peripheral blood smear revealing gray-colored platelets
- Bone marrow biopsy indicating myelofibrosis
- Genetic testing confirming mutations in the NBEAL2 gene
Treatment[edit]
There is no specific cure for Gray platelet syndrome. Management focuses on preventing and treating bleeding episodes. Treatment options include:
- Platelet transfusions during severe bleeding episodes or surgical procedures
- Use of antifibrinolytic agents such as tranexamic acid to reduce bleeding
- Hormonal therapy to manage menorrhagia in women
Prognosis[edit]
The prognosis for individuals with Gray platelet syndrome varies. While many patients experience mild to moderate bleeding symptoms, the development of myelofibrosis can lead to more serious complications. Regular monitoring and supportive care are essential to manage the condition effectively.
See also[edit]
References[edit]
External Links[edit]
-
